Century Therapeutics stock fell 10.81 percent on October 6

Published on 10/07/2026 at 03:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Century Therapeutics stock reported Q2 2026 EPS of negative USD 0.17 versus a negative USD 0.11 consensus estimate. CNTY-813 held glycemic control for more than 11 months in mice.

IPSC, US15673T1007, Illustration mit AI erstellt.

Century Therapeutics (ISIN US15673T1007) stock was last at USD 1.32 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 10.81 percent from the previous session. The move leaves the clinical-stage biotechnology company trading near the lower end of its USD 0.43 to USD 3.04 52-week range.

IPSC stock absorbs a sharp setback

The latest market signal came as Century continues to advance CNTY-813, an investigational iPSC-derived islet replacement therapy for type 1 diabetes. The company presented new nonclinical data at the European Association for the Study of Diabetes meeting on October 2, 2026.

According to StockTitan, the data showed glycemic control lasting more than 11 months in diabetic mice until graft removal. The filing also described five clinical-scale production runs, successful liver engraftment in rats and preserved function after 96 hours of cold storage.

Q2 loss missed the consensus mark

Century reported diluted earnings per share of negative USD 0.17 for the second quarter of 2026, compared with a negative USD 0.11 consensus estimate. The USD 0.06 shortfall gives the October share-price decline a financial counterpart beyond the development-stage pipeline.

MarketBeat identifies the company as a Nasdaq-listed biotechnology issuer and reports the August 12, 2026 earnings release date. The same report lists a Hold consensus based on seven analysts, with an average price target of USD 4.75, a high target of USD 8.00 and a low target of USD 2.00.

Measured against the USD 1.32 price on October 6, 2026, the average target lies 259.8 percent above the stock price. That gap reflects the binary profile of a company whose valuation depends heavily on clinical execution and regulatory progress.

Clinical milestone remains ahead

StockTitan reports that Century expects to submit the CNTY-813 Investigational New Drug application in the fourth quarter of 2026 and anticipates initial clinical data in the second half of 2027. These milestones remain forward-looking and depend on completion of the remaining IND-enabling studies.

For investors, the central contrast is clear: preclinical results have produced measurable development milestones, while the latest quarterly loss and the 10.81 percent session decline show that the market still prices substantial clinical and regulatory risk.

IPSC stock remains near its yearly low

Century Therapeutics stock was last at USD 1.32 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. Its market capitalization was USD 239.0 million and session volume was 2,715,528 shares.